0000000000088950

AUTHOR

Elke Leinisch

showing 2 related works from this author

Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre …

2021

Summary Background Systematic electrocardiogram (ECG) monitoring improves detection of covert atrial fibrillation in stroke survivors but the effect on secondary prevention is unknown. We aimed to assess the effect of systematic ECG monitoring of patients in hospital on the rate of oral anticoagulant use after 12 months. Methods In this investigator-initiated, randomised, open-label, parallel-group multicentre study with masked endpoint adjudication, we recruited patients aged at least 18 years with acute ischaemic stroke or transient ischaemic attack without known atrial fibrillation in 38 certified stroke units in Germany. Patients were randomly assigned (1:1) to usual diagnostic procedur…

Malemedicine.medical_specialtyepidemiology [Atrial Fibrillation]methods [Electrocardiography]Populationdiagnosis [Ischemic Stroke]030204 cardiovascular system & hematologyBrain Ischemia03 medical and health sciencesElectrocardiography0302 clinical medicineRisk FactorsInternal medicineIschaemic strokeAtrial Fibrillationdiagnosis [Brain Ischemia]medicineepidemiology [Brain Ischemia]HumansIn patientMyocardial infarctionddc:610educationepidemiology [Ischemic Stroke]Ischemic StrokeMonitoring PhysiologicAgedAged 80 and overeducation.field_of_studybusiness.industryphysiopathology [Ischemic Stroke]Hazard ratiodiagnosis [Atrial Fibrillation]Atrial fibrillationOdds ratioMiddle Agedmethods [Monitoring Physiologic]medicine.diseasephysiopathology [Atrial Fibrillation]physiopathology [Brain Ischemia]3. Good healthFemaleNeurology (clinical)Open labelbusiness030217 neurology & neurosurgery
researchProduct

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases

2020

Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for thrombolysis with recombinant tissue-type plasminogen activator (rt-PA). In patients on dabigatran with intracerebral hemorrhage idarucizumab could prevent lesion growth. Aims To provide insights into the clinical use of idarucizumab in patients under effective dabigatran anticoagulation presenting with signs of acute ischemic stroke or intracranial hemorrhage. Methods Retrospective data collected from German neurological/neurosurgical departments ad…

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentMedizinAntibodies Monoclonal HumanizedAntithrombinsBrain IschemiaDabigatranGermanyInternal medicinemedicineHumansThrombolytic Therapyddc:610Ischemic StrokeRetrospective StudiesIntracerebral hemorrhagebusiness.industryAnticoagulantWarfarinIdarucizumabAtrial fibrillationThrombolysisVitamin K antagonistmedicine.diseaseDabigatranStrokeNeurologyCardiologybusinessIntracranial Hemorrhagesmedicine.drugInternational Journal of Stroke
researchProduct